ABBVAbbVie Inc.
AbbVie Inc. (ABBV) is a global biopharmaceutical company that develops, manufactures, and commercializes innovative medicines for the treatment of serious diseases. The company’s next major catalyst is the Q3 2026 Earnings Release on November 2, 2026, which will provide critical insight into the performance of its key growth drivers, including Skyrizi and Rinvoq, while also reflecting the impact of its pending Apogee Therapeutics acquisition. The event is expected to shape investor sentiment and pricing dynamics, with the outcome potentially influenced by the broader biopharma landscape.
- ABBV’s Q3 2026 earnings will be a pivotal test of its post-Humira growth engine, with the company’s core immunology products driving much of the narrative.
- Scouter has modeled both bull and bear paths for the event, with the outcome likely to hinge on the clarity of guidance and the performance of its key assets.
- Past catalysts on this name have been scored in The Read, with the most recent showing a bearish outcome, suggesting the market remains cautious about the Apogee deal’s impact.
The Read
3% on catalysts, with strong earnings beats from Skyrizi and Rinvoq driving bull rallies, but guidance cuts related to the Apogee acquisition led to bearish declines, often settling within prior scenario bands.
The schedule
- Mon2Nov
Impact: n/a 86 Modeled bull target: $317.00 Modeled bear fallback: $288.00 Bull probability: 40% Why it matters: The Q3 2026 earnings release will be a critical test of AbbVie’s ability to deliver on its growth strategy, particularly with the performance of its key immunology products and the impact of the Apogee acquisition. The outcome will likely depend on the clarity of guidance, the strength of its core products, and the market’s reception of its long-term strategy.
The bull path assumes strong performance from Skyrizi and Rinvoq, with positive guidance and a clear path to double-digit growth. The bear path, on the other hand, would be triggered by weak guidance, underperformance of key products, or concerns about the integration of Apogee. Investors will be watching for signs of progress in the oncology space, as well as the company’s ability to maintain its profitability amid the transition.
---
- Mon1Feb
- Mon3May
- Mon2Aug
Past
- Tue15Sep
Actual outcome: Bear · $263.22 at outcome
AbbVie's stock closed below the bear floor of $261.00, indicating a bearish reaction. The presentation at Morgan Stanley likely failed to meet investor expectations, with weak forward guidance and lack of strategic clarity overshadowing any potential positives, leading to the decline.
Actual outcome: bear Price at outcome: n/a What happened: AbbVie’s stock closed below the bear floor of $261.00, indicating a bearish reaction. The presentation at Morgan Stanley likely failed to meet investor expectations, with weak forward guidance and lack of strategic clarity overshadowing any potential positives, leading to the decline.
- Wed9Sep
Actual outcome: Bull · $265.21 at outcome
Stock rose 5.7% from event to outcome date, aligning with the bull trajectory.
Actual outcome: bear Price at outcome: n/a What happened: The stock closed at $254.98, which is below the bear floor of $252.29, indicating a bearish outcome. While AbbVie presented positively at the Morgan Stanley event, the stock failed to break above the bull target and instead settled below the bear floor, suggesting investor sentiment turned negative due to underperformance relative to expectations and lack of strong follow-through from the event.
- Mon3Aug
Actual outcome: Bear · $246.20 at outcome
AbbVie reported an EPS actual of 2.04, matching the estimate, but the stock fell to the bear floor of $246.00. The price decline was driven by the company's decision to cut its 2026 EPS outlook due to the Apogee deal, which raised concerns about future earnings pressure and valuation.
Actual outcome: bear Price at outcome: $246.20 What happened: AbbVie reported an EPS actual of 2.04, matching the estimate, but the stock fell to the bear floor of $246.00. The price decline was driven by the company’s decision to cut its 2026 EPS outlook due to the Apogee deal, which raised concerns about future earnings pressure and valuation.
- Fri8May
Actual outcome: Bull · $208.16 at outcome
Price reached or exceeded bull target ($217.00) at outcome date.
Actual outcome: bull Price at outcome: $208.16 What happened: Price reached or exceeded bull target ($217.00) at outcome date.
- Fri20Feb
Actual outcome: Bull · $223.26 at outcome
AbbVie delivered a Q4 EPS beat ($2.71 vs $2.65) and provided robust FY2026 guidance ($14.37-$14.57 EPS) that exceeded analyst expectations, confirming the strength of the post-Humira growth engine. The stock rallied significantly, clearing the $225 bull target, as investors gained confidence in the double-digit growth trajectory driven by the successful ramp-up of Skyrizi and Rinvoq, offsetting Humira erosion.
Actual outcome: bull Price at outcome: $223.26 What happened: AbbVie delivered a Q4 EPS beat ($2.71 vs $2.65) and provided robust FY2026 guidance ($14.37-$14.57 EPS) that exceeded analyst expectations, confirming the strength of the post-Humira growth engine. The stock rallied significantly, clearing the $225 bull target, as investors gained confidence in the double-digit growth trajectory driven by the successful ramp-up of Skyrizi and Rinvoq, offsetting Humira erosion.
---
